Search

Your search keyword '"Yoganathan, Thulaciga"' showing total 17 results
Start Over Author "Yoganathan, Thulaciga"
17 results on '"Yoganathan, Thulaciga"'

1. Author Correction: Acute stress induces long-term metabolic, functional, and structural remodeling of the heart

Author

Yoganathan, Thulaciga, Perez-Liva, Mailyn, Balvay, Daniel, Le Gall, Morgane, Lallemand, Alice, Certain, Anais, Autret, Gwennhael, Mokrani, Yasmine, Guillonneau, François, Bruce, Johanna, Nguyen, Vincent, Gencer, Umit, Schmitt, Alain, Lager, Franck, Guilbert, Thomas, Bruneval, Patrick, Vilar, Jose, Maissa, Nawal, Mousseaux, Elie, Viel, Thomas, Renault, Gilles, Kachenoura, Nadjia, and Tavitian, Bertrand

Published
2023
Full Text
View/download PDF

2. Acute stress induces long-term metabolic, functional, and structural remodeling of the heart

Author

Yoganathan, Thulaciga, Perez-Liva, Mailyn, Balvay, Daniel, Le Gall, Morgane, Lallemand, Alice, Certain, Anais, Autret, Gwennhael, Mokrani, Yasmine, Guillonneau, François, Bruce, Johanna, Nguyen, Vincent, Gencer, Umit, Schmitt, Alain, Lager, Franck, Guilbert, Thomas, Bruneval, Patrick, Vilar, Jose, Maissa, Nawal, Mousseaux, Elie, Viel, Thomas, Renault, Gilles, Kachenoura, Nadjia, and Tavitian, Bertrand

Published
2023
Full Text
View/download PDF

3. Implementation of a Product Lifecycle Management System for Biomedical Research

Author

Raboudi, Amel, Hervé, Pierre-Yves, Allanic, Marianne, Balvay, Daniel, Duarte, Roberto, Bakayako, Ismael, Viel, Thomas, Certain, Anais, Yoganathan, Thulaciga, Boutinaud, Philippe, Durupt, Alexandre, Tavitian, Bertrand, Eynard, Benoît, Rannenberg, Kai, Editor-in-Chief, Soares Barbosa, Luís, Editorial Board Member, Goedicke, Michael, Editorial Board Member, Tatnall, Arthur, Editorial Board Member, Neuhold, Erich J., Editorial Board Member, Stiller, Burkhard, Editorial Board Member, Tröltzsch, Fredi, Editorial Board Member, Pries-Heje, Jan, Editorial Board Member, Kreps, David, Editorial Board Member, Reis, Ricardo, Editorial Board Member, Furnell, Steven, Editorial Board Member, Mercier-Laurent, Eunika, Editorial Board Member, Winckler, Marco, Editorial Board Member, Malaka, Rainer, Editorial Board Member, Canciglieri Junior, Osiris, editor, Noël, Frédéric, editor, Rivest, Louis, editor, and Bouras, Abdelaziz, editor

Published
2022
Full Text
View/download PDF

6. Implementation of a Product Lifecycle Management System for Biomedical Research

Author

Raboudi, Amel, primary, Hervé, Pierre-Yves, additional, Allanic, Marianne, additional, Balvay, Daniel, additional, Duarte, Roberto, additional, Bakayako, Ismael, additional, Viel, Thomas, additional, Certain, Anais, additional, Yoganathan, Thulaciga, additional, Boutinaud, Philippe, additional, Durupt, Alexandre, additional, Tavitian, Bertrand, additional, and Eynard, Benoît, additional

Published
2022
Full Text
View/download PDF

13. Sunitinib-induced cardiac hypertrophy and the endothelin axis

Author

Sourdon, Joevin, Facchin, Caterina, Certain, Anaïs, Viel, Thomas, Robin, Blaise, Lager, Franck, Marchiol, Carmen, Balvay, Daniel, Yoganathan, Thulaciga, Favier, Judith, Tharaux, Pierre-Louis, Dhaun, Neeraj, Renault, Gilles, Tavitian, Bertrand, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and Sourdon, Joevin

Subjects
Endothelin Receptor Antagonists, metabolic imaging, sunitinib, cardiotoxicity, Mice, Nude, Cardiomegaly, urologic and male genital diseases, Mice, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Animals, Precision Medicine, Sulfonamides, Ventricular Remodeling, Endothelins, cardiac hypertrophy, Fibrosis, female genital diseases and pregnancy complications, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Mice, Inbred C57BL, Disease Models, Animal, Pyrimidines, Hypertension, cardiovascular system, Female, endothelin, Glycolysis, Research Paper
Abstract

International audience; Anti-angiogenics drugs in clinical use for cancer treatment induce cardiotoxic side effects. The endothelin axis is involved in hypertension and cardiac remodelling, and addition of an endothelin receptor antagonist to the anti-angiogenic sunitinib was shown to reduce cardiotoxicity of sunitinib in mice. Here, we explored further the antidote effect of the endothelin receptor antagonist macitentan in sunitinib-treated animals on cardiac remodeling. Methods: Tumor-bearing mice treated per os daily by sunitinib or vehicle were imaged before and after 1, 3 and 6 weeks of treatment by positron emission tomography using [ 18 F]fluorodeoxyglucose and by echocardiography. Non-tumor-bearing animals were randomly assigned to be treated per os daily by vehicle or sunitinib or macitentan or sunitinib+macitentan, and imaged by echocardiography after 5 weeks. Hearts were harvested for histology and molecular analysis at the end of in vivo exploration. Results: Sunitinib treatment increases left ventricular mass and ejection fraction and induces cardiac fibrosis. Sunitinib also induces an early increase in cardiac uptake of [ 18 F]fluorodeoxyglucose, which is significantly correlated with increased left ventricular mass at the end of treatment. Co-administration of macitentan prevents sunitinib-induced hypertension, increase in ejection fraction and cardiac fibrosis, but fails to prevent increase of the left ventricular mass. Conclusion: Early metabolic changes predict sunitinib-induced cardiac remodeling. Endothelin blockade can prevent some but not all cardiotoxic side-effects of sunitinib, in particular left ventricle hypertrophy that appears to be induced by sunitinib through an endothelin-independent mechanism.

Published
2021

14. Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment

Author

Facchin, Caterina, Perez-Liva, Mailyn, Garofalakis, Anikitos, Viel, Thomas, Certain, Anais, Balvay, Daniel, Yoganathan, Thulaciga, Woszczyk, Justine, De Sousa, Kelly, Sourdon, Joevin, Provost, Jean, Tanter, Mickael, Lussey-Lepoutre, Charlotte, Favier, Judith, Tavitian, Bertrand, Sourdon, Joevin, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Biospace Lab, BIOSPACE Lab, École Polytechnique de Montréal (EPM), Montreal Heart Institute - Institut de Cardiologie de Montréal, Physique pour la médecine (PhysMed Paris), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Physique pour la médecine (UMR 8063, U1273), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
angiogenesis, paraganglioma, positron emission tomography, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.CAN]Life Sciences [q-bio]/Cancer, SDHB, ultrafast-ultrasound imaging, Cancer metabolism, multimodality imaging
Abstract

International audience; Rationale: Deregulation of metabolism and induction of vascularization are major hallmarks of cancer. Using a new multimodal preclinical imaging instrument, we explored a sequence of events leading to sunitinib-induced resistance in a murine model of paraganglioma (PGL) invalidated for the expression of succinate dehydrogenase subunit B (Sdhb-/-). Methods: Two groups of Sdhb-/-tumors bearing mice were treated with sunitinib (6 weeks) or vehicle (3 weeks). Concurrent Positron Emission Tomography (PET) with 2′-deoxy-2′-[ 18 F]fluoro-D-glucose (FDG), Computed Tomography (CT) and Ultrafast Ultrasound Imaging (UUI) imaging sessions were performed once a week and ex vivo samples were analyzed by western blots and histology. Results: PET-CT-UUI enabled to detect a rapid growth of Sdhb-/-tumors with increased glycolysis and vascular development. Sunitinib treatment prevented tumor growth, vessel development and reduced FDG uptake at week 1 and 2 (W1-2). Thereafter, imaging revealed tumor escape from sunitinib treatment: FDG uptake in tumors increased at W3, followed by tumor growth and vessel development at W4-5. Perfused vessels were preferentially distributed in the hypermetabolic regions of the tumors and the perfused volume increased during escape from sunitinib treatment. Finally, initial changes in total lesion glycolysis and maximum vessel length at W1 were predictive of resistance to sunitinib. Conclusion: These results demonstrate an adaptive resistance of Sdhb-/-tumors to six weeks of sunitinib treatment. Early metabolic changes and delayed vessel architecture changes were detectable and predictable in vivo early during anti-angiogenic treatment. Simultaneous metabolic, anatomical and functional imaging can monitor precisely the effects of anti-angiogenic treatment of tumors.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results